As advancements in medical research continue to unfold, hope brightens for individuals living with cystic fibrosis (CF).

Approximately 300 families with children aged 2-5 who have at least one F508del mutation, are waiting for Trikafta. With the Pharmaceutical Benefits Advisory Committee meeting being held later this week, we hope a positive outcome will be reached.

Loxegen's nanoparticle gene therapy for cystic fibrosis (CF) has secured a significant $1.5 million grant from the Australian Government’s $230m Medical Research Future Fund (MRFF), with additional contributions pushing the total funding to over $3million

In Australia, as across the globe, the rising cost of living continues to be a pressing concern for many, significantly affecting those living with chronic conditions such as cystic fibrosis (CF).